2024.11.05 21:14 GMT+8

GSK: AREXVY APPROVED IN CANADA FOR PREVENTION OF LOWER RESPIRATORY TRACT DISEASE CAUSED BY RSV IN ADULTS 50-59 YEARS OF AGE WHO ARE AT INCREASED RISK

Updated 2024.11.05 21:14 GMT+8
CGTN
Copyright © 

RELATED STORIES